‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The Federal Trade Commission and seven states say Shkreli should be held in contempt
Photo: Rômulo Queiroz / Pexels
Reported by MarketWatch.
Read the full story at MarketWatch
